GGrantIndex
← Leaderboards

William Paul Duprex

Icahn School Of Medicine At Mount Sinai

$23,556,651
Attributed
$25,337,552
Total exposure
11
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $11.5M · FY201125
$20M$15M$10M$5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$33,397,444 · 12

By mechanism

UC7$16,327,635 · 7
G20$6,659,737 · 1
U19$5,674,171 · 1
R01$4,515,359 · 2
R21$220,542 · 1

Top collaborators

Most similar at Icahn School Of Medicine At Mount Sinai

Same institution · by research overlap

Others in their field

Top investigators on “Animals

Research focus

AnimalsInfectionPathogenIn VivoPathogenesisProgramsPandemic DiseaseCellsBiologicalEmerging Communicable DiseasesViralEnsureLaboratoriesOperationEmerging PathogenEventUniversitiesBiodefensePandemic PreparednessTransmission ProcessComplexResponseBiologyResearch Personnel

Grant awards (29)

Pitt RBL$2,594,826
UC7 · FY2025 · AI · contact PI
Operations Core$982,724
UC7 · FY2025 · AI · contact PI
Integrated Services Core$895,766
UC7 · FY2025 · AI · contact PI
Practices Core$716,336
UC7 · FY2025 · AI · contact PI
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization$535,044
R01 · FY2025 · AI
Prototype strategy for vaccines and antibodies to rubulaviruses$5,674,171
U19 · FY2024 · AI · contact PI
Pitt RBL$2,594,826
UC7 · FY2024 · AI · contact PI
Operations Core$1,006,216
UC7 · FY2024 · AI · contact PI
Integrated Services Core$879,285
UC7 · FY2024 · AI · contact PI
Practices Core$709,325
UC7 · FY2024 · AI · contact PI
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization$587,096
R01 · FY2024 · AI
Pitt RBL$2,870,240
UC7 · FY2023 · AI · contact PI
Integrated Services Core$1,158,560
UC7 · FY2023 · AI · contact PI
Operations Core$984,552
UC7 · FY2023 · AI · contact PI
Practices Core$727,128
UC7 · FY2023 · AI · contact PI
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization$614,795
R01 · FY2023 · AI
Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research$3,329,737
G20 · FY2022 · AI · contact PI
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization$769,010
R01 · FY2022 · AI
Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research$3,330,000
G20 · FY2021 · AI · contact PI
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation$409,250
R01 · FY2017 · AI · contact PI
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation$409,250
R01 · FY2016 · AI · contact PI
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation$409,250
R01 · FY2015 · AI · contact PI
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation$404,154
R01 · FY2014 · AI · contact PI
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation$377,510
R01 · FY2013 · AI · contact PI
Cell and Tissue Imaging Core$29,152
UC7 · FY2013 · AI · contact PI
Multimodal imaging of antibody-mediated therapy during acute viral encephalitides$22,035
R21 · FY2013 · AI
Multimodal imaging of antibody-mediated therapy during acute viral encephalitides$198,507
R21 · FY2012 · AI
Cell and Tissue Imaging Core$107,808
UC7 · FY2012 · AI · contact PI
Cell and Tissue Imaging Core$70,891
UC7 · FY2011 · AI · contact PI